Medicinova (MNOV) Amortization of Deferred Charges (2011 - 2022)
Medicinova's (MNOV) quarterly Amortization of Deferred Charges came in at $45179.0 in Q1 2022, down 19.04% year-on-year from $55806.0 in Q1 2021, and down 19.04% on a QoQ basis from $55806.0 in Q1 2021.
Medicinova (MNOV) Amortization of Deferred Charges (2011 - 2022) Analysis & Trends
Medicinova (MNOV) has 3 years of Amortization of Deferred Charges data on file, last reported at $45179.0 in Q1 2022.
- On a quarterly basis, Amortization of Deferred Charges fell 19.04% year-over-year to $45179.0 in Q1 2022; TTM through Mar 2022 was $99947.0, a N/A change from a year earlier, with the FY2021 full-year figure at $216640.0, up 3.06% from the prior year.
- Amortization of Deferred Charges for Q1 2022 stood at $45179.0, down from $55806.0 in the prior quarter.
- Over the last five years, Amortization of Deferred Charges for MNOV reached as high as $55806.0 in Q1 2021 and fell as low as $45179.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 469.68 Bn | 464.89 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.76 Bn | 115.51 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.40 Bn | 61.65 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.88 Bn | 50.69 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn |
| 10 | Medicinova | 64.52 Mn | 64.52 Mn | 4,754.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 45,179.00 |
| Mar 31, 2022 | 45,179.00 |
| Mar 31, 2021 | 55,806.00 |
| Mar 31, 2021 | 55,806.00 |
| Sep 30, 2011 | -1,038.00 |
| Sep 30, 2011 | -1,038.00 |